Stock Research for AERI

AERI

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

AERI Stock Chart & Research Data

The AERI chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the AERI chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


AERI Due diligence Resources & Stock Charts

The AERI stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View AERI Detailed Price Forecast - CNN Money CNN View AERI Detailed Summary - Google Finance
Yahoo View AERI Detailed Summary - Yahoo! Finance Zacks View AERI Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View AERI Trends & Analysis - Trade-Ideas Barrons View AERI Major Holders - Barrons
NASDAQ View AERI Call Transcripts - NASDAQ Seeking View AERI Breaking News & Analysis - Seeking Alpha
Spotlight View AERI Annual Report - CompanySpotlight.com OTC Report View AERI OTC Short Report - OTCShortReport.com
TradeKing View AERI Fundamentals - TradeKing Charts View AERI SEC Filings - Bar Chart
WSJ View Historical Prices for AERI - The WSJ Morningstar View Performance/Total Return for AERI - Morningstar
MarketWatch View the Analyst Estimates for AERI - MarketWatch CNBC View the Earnings History for AERI - CNBC
StockMarketWatch View the AERI Earnings - StockMarketWatch MacroAxis View AERI Buy or Sell Recommendations - MacroAxis
Bullish View the AERI Bullish Patterns - American Bulls Short Pains View AERI Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View AERI Stock Mentions - StockTwits PennyStocks View AERI Stock Mentions - PennyStockTweets
Twitter View AERI Stock Mentions - Twitter Invest Hub View AERI Investment Forum News - Investor Hub
Yahoo View AERI Stock Mentions - Yahoo! Message Board Seeking Alpha View AERI Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for AERI - SECform4.com Insider Cow View Insider Transactions for AERI - Insider Cow
CNBC View AERI Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for AERI - OTC Markets
Yahoo View Insider Transactions for AERI - Yahoo! Finance NASDAQ View Institutional Holdings for AERI - NASDAQ


Stock Charts

FinViz View AERI Stock Insight & Charts - FinViz.com StockCharts View AERI Investment Charts - StockCharts.com
BarChart View AERI Stock Overview & Charts - BarChart Trading View View AERI User Generated Charts - Trading View




Latest Financial News for AERI


Aerie Pharmaceuticals Initiates Netarsudil Ophthalmic Solution Phase 2 Clinical Trial in Japan Designed to Support Requirements for Future Regulatory Filing
Posted on Thursday March 21, 2019

Aerie Pharmaceuticals, Inc. (AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced the commencement of patient dosing in its Phase 2 clinical trial designed in accordance with the requirements of Japan’s PMDA (Pharmaceuticals and Medical Devices Agency) to support potential regulatory submission of netarsudil ophthalmic solution in Japan. Netarsudil ophthalmic solution 0.02% is known by the name Rhopressa® in the United States and is approved for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.


Aerie (AERI) Starts Phase II Study on Eye Candidate AR-1105
Posted on Tuesday March 19, 2019

Aerie (AERI) begins dosing in a phase II study on AR-1105 for treating patients with macular edema due to retinal vein occlusion.


Aerie Pharmaceuticals Initiates Phase 2 Clinical Trial of AR-1105 (Dexamethasone Intravitreal Implant) in Patients with Macular Edema Associated with Retinal Vein Occlusion
Posted on Monday March 18, 2019

Aerie Pharmaceuticals, Inc. (AERI) (Aerie), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced the commencement of patient dosing in a Phase 2 clinical trial of AR-1105, its investigational dexamethasone intravitreal implant, in patients with macular edema due to retinal vein occlusion (RVO). This Phase 2 study (AR1105-CS201) will be conducted at approximately 20 centers in the United States and enroll up to 45 patients. In the initial safety stage, up to 5 patients will be enrolled in a single cohort to receive clinical formulation #1 (CF-1), delivering a 340µg dose of dexamethasone in a single intravitreal injection.


Aerie (AERI) Receives FDA Nod for Rocklatan to Treat Glaucoma
Posted on Wednesday March 13, 2019

Aerie (AERI) gets FDA approval for Rocklatan to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension and announces its 2019 revenue and cash burn outlook.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.